bioAffinity Technologies Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification Number) |
(Address of principal executive offices and Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e- 4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
|
|
|
| |
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On August 12, 2025, the board of directors (the “Board”) of bioAffinity, Inc. (the “Company”) appointed Roberto Rios, CPA and John J. Oppenheimer, M.D. as members of the Board, each with an initial term expiring at the Company’s 2026 annual meeting of stockholders.
Neither Mr. Rios nor Dr. Oppenheimer was selected as a director pursuant to any arrangements or understandings with the Company or with any other person, and there are no related party transactions between either Mr. Rios or Dr. Oppenheimer and the Company that would require disclosure under Item 404(a) of Regulation S-K. The annual compensation of Mr. Rios and Dr. Oppenheimer will be consistent with that provided to the Company’s other non-employee directors.
On August 12, 2025, Gary Rubin informed the Board of the Company that he was resigning from the Board and from the Nominating and Corporate Governance Committee effective immediately. Mr. Rubin’s resignation was not the result of any disagreement with the Company or the Board on any matters relating to the operations, policies or practices.
In connection with the appointments of Mr. Rios and Dr. Oppenheimer and the resignation of Mr. Rubin, the Board appointed Mr. Rios as the Chair of the Audit Committee and as a member of the Compensation Committee. Dr. Oppenheimer was appointed to serve on the Nominating and Corporate Governance Committee. In addition, the Board appointed Jamie Platt to serve on the Audit Committee, Robert Anderson to serve on the Compensation Committee, and Jamie Platt to serve as the Chair of the Nominating and Corporate Governance Committee.
Item 8.01. Other Events.
On August 18, 2025, the Company issued a press release announcing the appointments of Mr. Rios and Dr. Oppenheimer as directors of the Company. A copy of the press release is attached hereto as Exhibit 99.1, which is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit No. | Description | |
| 99.1 | Press release dated August 18, 2025 | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
| -2- |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: August 18, 2025 | BIOAFFINITY TECHNOLOGIES, INC. (Registrant) | |
| By: | /s/ Maria Zannes | |
| Name: | Maria Zannes | |
| Title: | President and Chief Executive Officer | |
| -3- |